A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure

A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure : A Nationwide Cohort Study. / Johansen, Niklas Dyrby; Vaduganathan, Muthiah; Zahir, Deewa; Fiuzat, Mona; Defilippis, Ersilia M.; Januzzi, James L.; Butler, Javed; O'Connor, Christopher M.; Abraham, William T.; Psotka, Mitchell A.; McMurray, John J.V.; Dewan, Pooja; Claggett, Brian L.; Solomon, Scott D.; Modin, Daniel; Butt, Jawad H.; Jensen, Jens Ulrik Stæhr; Schou, Morten; Torp-Pedersen, Christian; Køber, Lars; Gislason, Gunnar H.; Biering-Sørensen, Tor.

In: Circulation: Heart Failure, Vol. 16, No. 2, E009729, 2023.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Johansen, ND, Vaduganathan, M, Zahir, D, Fiuzat, M, Defilippis, EM, Januzzi, JL, Butler, J, O'Connor, CM, Abraham, WT, Psotka, MA, McMurray, JJV, Dewan, P, Claggett, BL, Solomon, SD, Modin, D, Butt, JH, Jensen, JUS, Schou, M, Torp-Pedersen, C, Køber, L, Gislason, GH & Biering-Sørensen, T 2023, 'A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study', Circulation: Heart Failure, vol. 16, no. 2, E009729. https://doi.org/10.1161/CIRCHEARTFAILURE.122.009729

APA

Johansen, N. D., Vaduganathan, M., Zahir, D., Fiuzat, M., Defilippis, E. M., Januzzi, J. L., Butler, J., O'Connor, C. M., Abraham, W. T., Psotka, M. A., McMurray, J. J. V., Dewan, P., Claggett, B. L., Solomon, S. D., Modin, D., Butt, J. H., Jensen, J. U. S., Schou, M., Torp-Pedersen, C., ... Biering-Sørensen, T. (2023). A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study. Circulation: Heart Failure, 16(2), [E009729]. https://doi.org/10.1161/CIRCHEARTFAILURE.122.009729

Vancouver

Johansen ND, Vaduganathan M, Zahir D, Fiuzat M, Defilippis EM, Januzzi JL et al. A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study. Circulation: Heart Failure. 2023;16(2). E009729. https://doi.org/10.1161/CIRCHEARTFAILURE.122.009729

Author

Johansen, Niklas Dyrby ; Vaduganathan, Muthiah ; Zahir, Deewa ; Fiuzat, Mona ; Defilippis, Ersilia M. ; Januzzi, James L. ; Butler, Javed ; O'Connor, Christopher M. ; Abraham, William T. ; Psotka, Mitchell A. ; McMurray, John J.V. ; Dewan, Pooja ; Claggett, Brian L. ; Solomon, Scott D. ; Modin, Daniel ; Butt, Jawad H. ; Jensen, Jens Ulrik Stæhr ; Schou, Morten ; Torp-Pedersen, Christian ; Køber, Lars ; Gislason, Gunnar H. ; Biering-Sørensen, Tor. / A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure : A Nationwide Cohort Study. In: Circulation: Heart Failure. 2023 ; Vol. 16, No. 2.

Bibtex

@article{d97a18cf30a04cc890494c97b921a5ce,

title = "A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study",

abstract = "Background: As heart failure therapeutic care becomes increasingly complex, a composite medical therapy score could be useful to conveniently summarize background medical therapy. We applied the composite medical therapy score developed by the Heart Failure Collaboratory (HFC) to the Danish heart failure with reduced ejection fraction population to evaluate its external validation including assessing the distribution of the score and its association with survival. Methods: In a retrospective nationwide cohort study, we identified all Danish heart failure with reduced ejection fraction patients alive on July 1, 2018, and assessed their treatment doses. Patients were excluded if they did not have at least 365 days for up-titration of medical therapy prior to identification. The HFC score (range 0-8) accounts for use and dosing of multiple therapies prescribed to each patient. Risk-adjusted association between the composite score and all-cause mortality was examined. Results: In total, 26 779 patients (mean age 71.9 years; 32% women) were identified. At baseline, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker was used in 77%, β-blocker in 81%, mineralocorticoid receptor antagonist in 30%, angiotensin receptor-neprilysin inhibitor in 2%, and ivabradine in 2%. The median HFC score was 4. After multivariable adjustment, higher HFC scores were independently associated with lower mortality (≥median versus ",

keywords = "drug therapy, epidemiology, heart failure, mortality, survival analysis",

author = "Johansen, {Niklas Dyrby} and Muthiah Vaduganathan and Deewa Zahir and Mona Fiuzat and Defilippis, {Ersilia M.} and Januzzi, {James L.} and Javed Butler and O'Connor, {Christopher M.} and Abraham, {William T.} and Psotka, {Mitchell A.} and McMurray, {John J.V.} and Pooja Dewan and Claggett, {Brian L.} and Solomon, {Scott D.} and Daniel Modin and Butt, {Jawad H.} and Jensen, {Jens Ulrik St{\ae}hr} and Morten Schou and Christian Torp-Pedersen and Lars K{\o}ber and Gislason, {Gunnar H.} and Tor Biering-S{\o}rensen",

year = "2023",

doi = "10.1161/CIRCHEARTFAILURE.122.009729",

language = "English",

volume = "16",

journal = "Circulation: Heart Failure",

issn = "1941-3289",

publisher = "Lippincott Williams & Wilkins",

number = "2",

}

RIS

TY - JOUR

T1 - A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure

T2 - A Nationwide Cohort Study

AU - Johansen, Niklas Dyrby

AU - Vaduganathan, Muthiah

AU - Zahir, Deewa

AU - Fiuzat, Mona

AU - Defilippis, Ersilia M.

AU - Januzzi, James L.

AU - Butler, Javed

AU - O'Connor, Christopher M.

AU - Abraham, William T.

AU - Psotka, Mitchell A.

AU - McMurray, John J.V.

AU - Dewan, Pooja

AU - Claggett, Brian L.

AU - Solomon, Scott D.

AU - Modin, Daniel

AU - Butt, Jawad H.

AU - Jensen, Jens Ulrik Stæhr

AU - Schou, Morten

AU - Torp-Pedersen, Christian

AU - Køber, Lars

AU - Gislason, Gunnar H.

AU - Biering-Sørensen, Tor

PY - 2023

Y1 - 2023

N2 - Background: As heart failure therapeutic care becomes increasingly complex, a composite medical therapy score could be useful to conveniently summarize background medical therapy. We applied the composite medical therapy score developed by the Heart Failure Collaboratory (HFC) to the Danish heart failure with reduced ejection fraction population to evaluate its external validation including assessing the distribution of the score and its association with survival. Methods: In a retrospective nationwide cohort study, we identified all Danish heart failure with reduced ejection fraction patients alive on July 1, 2018, and assessed their treatment doses. Patients were excluded if they did not have at least 365 days for up-titration of medical therapy prior to identification. The HFC score (range 0-8) accounts for use and dosing of multiple therapies prescribed to each patient. Risk-adjusted association between the composite score and all-cause mortality was examined. Results: In total, 26 779 patients (mean age 71.9 years; 32% women) were identified. At baseline, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker was used in 77%, β-blocker in 81%, mineralocorticoid receptor antagonist in 30%, angiotensin receptor-neprilysin inhibitor in 2%, and ivabradine in 2%. The median HFC score was 4. After multivariable adjustment, higher HFC scores were independently associated with lower mortality (≥median versus

AB - Background: As heart failure therapeutic care becomes increasingly complex, a composite medical therapy score could be useful to conveniently summarize background medical therapy. We applied the composite medical therapy score developed by the Heart Failure Collaboratory (HFC) to the Danish heart failure with reduced ejection fraction population to evaluate its external validation including assessing the distribution of the score and its association with survival. Methods: In a retrospective nationwide cohort study, we identified all Danish heart failure with reduced ejection fraction patients alive on July 1, 2018, and assessed their treatment doses. Patients were excluded if they did not have at least 365 days for up-titration of medical therapy prior to identification. The HFC score (range 0-8) accounts for use and dosing of multiple therapies prescribed to each patient. Risk-adjusted association between the composite score and all-cause mortality was examined. Results: In total, 26 779 patients (mean age 71.9 years; 32% women) were identified. At baseline, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker was used in 77%, β-blocker in 81%, mineralocorticoid receptor antagonist in 30%, angiotensin receptor-neprilysin inhibitor in 2%, and ivabradine in 2%. The median HFC score was 4. After multivariable adjustment, higher HFC scores were independently associated with lower mortality (≥median versus

KW - drug therapy

KW - epidemiology

KW - heart failure

KW - mortality

KW - survival analysis

UR - http://www.scopus.com/inward/record.url?scp=85148363590&partnerID=8YFLogxK

U2 - 10.1161/CIRCHEARTFAILURE.122.009729

DO - 10.1161/CIRCHEARTFAILURE.122.009729

M3 - Journal article

C2 - 36809039

AN - SCOPUS:85148363590

VL - 16

JO - Circulation: Heart Failure

JF - Circulation: Heart Failure

SN - 1941-3289

IS - 2

M1 - E009729

ER -

ID: 337995583